galactose has been researched along with l 743,872 in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avila, NA; Bacher, J; Francesconi, A; Groll, AH; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Walsh, TJ | 1 |
| Albert, ND; Kontoyiannis, DP; May, GS; Osherov, N | 1 |
| Glasmacher, A; Kartsonis, N; Layton, M; Maertens, J; Ngai, A; Ryan, D; Sable, C; Selleslag, D; Taylor, A | 1 |
| Mendlovic, S; Segal, E; Sionov, E | 1 |
| Chambers, ST; Scotter, JM | 1 |
| Bartlett, K; Risovic, V; Rosland, M; Sivak, O; Wasan, KM | 1 |
| Ahmad, S; Halim, MA; Khan, ZU; McGinnis, MR; Mokaddas, E; Nair, MP; Nampoory, MR; Said, T | 1 |
| Anaissie, EJ; Miceli, MH | 1 |
| Cantón, E; Chirivella, M; Crespo, M; Frasquet, J; Gobernado, M; Ortiz, R; Osseyran, F; Pemán, J; Pérez-Bellés, C; Quesada, A | 1 |
| Cheah, FK; Chlebicka, NL; Goh, YT; Kurup, A; Lin, RT; Low, JG; Tan, BH; Wong, GC | 1 |
| Jones, B; Kirkpatrick, WR; Lappin, DF; McCulloch, E; Patterson, TF; Rajendran, R; Ramage, G; Shrief, R; Warn, P; Williams, C | 1 |
| Al-Saigh, R; Meletiadis, J; Roilides, E; Velegraki, A; Walsh, TJ; Zerva, L | 1 |
| Datry, A; Elsendoorn, A; Fekkar, A; Godet, C; Herbrecht, R; Kauffmann-Lacroix, C; Letscher-Bru, V; Massias, L; Nivoix, Y; Pang, KA; Scholler, J; Uzunov, M | 1 |
| Baghaei, P; Droudinia, A; Javanmard, P; Mansouri, D; Marjani, M; Najafizadeh, K; Sarrafzadeh, SA; Soraghi, A; Tabarsi, P; Zandian, P | 1 |
| Afroz, S; Alam, MK; El-Ganiny, AM; Kaminskyj, SG; Liu, J; Sanders, DA | 1 |
| Chen, F; Shi, Y; Su, X; Sun, WK; Xu, XY; Zhang, M | 1 |
| Aimanianda, V; Dichtl, K; Ebel, F; Latgé, JP; Prévost, MC; Samantaray, S; Wagener, J; Zhu, Z | 1 |
| Barnes, R; Bow, E; Charbonneau, C; Earnshaw, S; Herbrecht, R; Kantecki, M; Maertens, J; McDade, C; Morrissey, O; Schlamm, H; Slavin, M; Weinstein, D | 1 |
1 review(s) available for galactose and l 743,872
| Article | Year |
|---|---|
[Native valve Aspergillus fumigatus endocarditis with blood culture positive and negative for galactomannan antigen. Case report and literature review].
Topics: Amaurosis Fugax; Aneurysm, Infected; Antifungal Agents; Antigens, Fungal; Aspergillosis; Aspergillus fumigatus; Biomarkers; Caspofungin; Combined Modality Therapy; Echinocandins; Endocarditis; False Negative Reactions; Fatal Outcome; Fungemia; Galactose; Heart Valve Prosthesis Implantation; Humans; Infarction; Kidney; Lipopeptides; Male; Mannans; Mesenteric Arteries; Mesenteric Vascular Occlusion; Middle Aged; Mitral Valve; Peptides, Cyclic; Pulmonary Disease, Chronic Obstructive; Pyrimidines; Renal Artery; Triazoles; Voriconazole | 2007 |
1 trial(s) available for galactose and l 743,872
| Article | Year |
|---|---|
Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Caspofungin; Drug Therapy, Combination; Echinocandins; Female; Fever; Galactose; Humans; Immunocompromised Host; Invasive Pulmonary Aspergillosis; Lipopeptides; Male; Mannans; Middle Aged; Mycoses; Neutropenia; Opportunistic Infections; Prospective Studies; Pyrimidines; Radiography, Thoracic; Risk Factors; Singapore; Tomography, X-Ray Computed; Treatment Outcome; Triazoles; Voriconazole | 2011 |
16 other study(ies) available for galactose and l 743,872
| Article | Year |
|---|---|
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Disease Models, Animal; Echinocandins; Female; Galactose; Lipopeptides; Lung Diseases, Fungal; Mannans; Microbial Sensitivity Tests; Neutropenia; Peptides; Peptides, Cyclic; Rabbits; Treatment Outcome | 2002 |
Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.
Topics: Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Cell Wall; DNA, Fungal; Drug Resistance, Microbial; Echinocandins; Fungal Proteins; Galactose; Glucose; Golgi Apparatus; Lipopeptides; Membrane Glycoproteins; Microbial Sensitivity Tests; Microscopy, Electron; Microscopy, Phase-Contrast; Peptides; Peptides, Cyclic; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Vesicular Transport Proteins | 2002 |
Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study.
Topics: Adult; Aged; Antifungal Agents; Antigens, Fungal; Aspergillosis; Caspofungin; Echinocandins; Enzyme-Linked Immunosorbent Assay; Female; Galactose; Humans; Lipopeptides; Lung Diseases, Fungal; Mannans; Middle Aged; Peptides, Cyclic; Treatment Outcome | 2005 |
Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Caspofungin; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Echinocandins; Female; Galactose; Granulocyte Colony-Stimulating Factor; Immunocompromised Host; Kidney; Lipopeptides; Liposomes; Lung; Mannans; Mice; Mice, Inbred ICR; Peptides, Cyclic; Polyenes; Survival Rate | 2005 |
Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate.
Topics: Animals; Antifungal Agents; Aspergillosis; Caspofungin; Disease Models, Animal; Echinocandins; Enzyme-Linked Immunosorbent Assay; Galactose; Lipopeptides; Liver Diseases; Male; Mannans; Neutropenia; Peptides, Cyclic; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Caspofungin; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Echinocandins; Galactose; Injections, Intravenous; Lipopeptides; Male; Mannans; Peptides, Cyclic; Phosphatidylcholines; Phosphatidylglycerols; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2007 |
Cerebral aspergillosis diagnosed by detection of Aspergillus flavus-specific DNA, galactomannan and (1-->3)-beta-D-glucan in clinical specimens.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus flavus; beta-Glucans; Brain; Brain Diseases; Caspofungin; Diagnosis, Differential; DNA, Fungal; Echinocandins; Electrophoresis, Agar Gel; Galactose; Humans; Lipopeptides; Male; Mannans; Middle Aged; Peptides, Cyclic; Polymerase Chain Reaction | 2007 |
When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all.
Topics: Adult; Antifungal Agents; Antigens, Fungal; Aspergillosis; beta-Glucans; Caspofungin; Echinocandins; Fungal Proteins; Galactose; Humans; Lipopeptides; Mannans; Peptides, Cyclic | 2007 |
Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillus fumigatus; Biomarkers; Caspofungin; Disease Models, Animal; DNA, Fungal; Early Diagnosis; Echinocandins; Galactose; Immunoenzyme Techniques; Invasive Pulmonary Aspergillosis; Lipopeptides; Mannans; Microbiological Techniques; Mycological Typing Techniques; Predictive Value of Tests; Rats; Real-Time Polymerase Chain Reaction; Time Factors; Triazoles | 2012 |
Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Aspergillus flavus; Aspergillus fumigatus; Caspofungin; Diffusion Chambers, Culture; Echinocandins; Galactose; Humans; Lipopeptides; Mannans; Microbial Sensitivity Tests; Pulsatile Flow; Pyrimidines; Species Specificity; Spores, Fungal; Triazoles; Voriconazole | 2012 |
Breakthrough invasive mould infections in patients treated with caspofungin.
Topics: Adult; Aged; Antifungal Agents; Caspofungin; Drug Resistance, Fungal; Echinocandins; Female; France; Fusariosis; Galactose; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hospitals, University; Humans; Lipopeptides; Male; Mannans; Middle Aged; Mucormycosis; Pulmonary Aspergillosis | 2012 |
Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients.
Topics: Adult; Antifungal Agents; Biomarkers; Bronchoalveolar Lavage Fluid; Caspofungin; Drug Therapy, Combination; Echinocandins; Galactose; Heart Transplantation; Humans; Invasive Pulmonary Aspergillosis; Lipopeptides; Lung Transplantation; Male; Mannans; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrimidines; Retrospective Studies; Sensitivity and Specificity; Transplantation; Triazoles; Voriconazole | 2012 |
Aspergillus nidulans galactofuranose biosynthesis affects antifungal drug sensitivity.
Topics: Antifungal Agents; Aspergillus nidulans; Biosynthetic Pathways; Caspofungin; Culture Media; Echinocandins; Fungal Proteins; Galactose; Gene Expression; Gene Expression Profiling; Hyphae; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction | 2012 |
Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.
Topics: Animals; Antifungal Agents; Aspergillus flavus; Aspergillus fumigatus; Aspergillus niger; Caspofungin; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Galactose; Humans; Lipopeptides; Male; Mannans; Microbial Sensitivity Tests; Neutropenia; Pulmonary Aspergillosis; Pyrimidines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Triazoles; Voriconazole | 2014 |
Aspergillus fumigatus devoid of cell wall β-1,3-glucan is viable, massively sheds galactomannan and is killed by septum formation inhibitors.
Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Benzenesulfonates; beta-Glucans; Caspofungin; Cell Wall; Chitin; Echinocandins; Galactose; Glucosyltransferases; Hyphae; Lipopeptides; Mannans; Mutation; Phenotype; Polysaccharides | 2015 |
Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Cost Savings; Decision Trees; Deoxycholic Acid; Drug Combinations; Echinocandins; Febrile Neutropenia; Galactose; Health Care Costs; Health Resources; Humans; Immunocompromised Host; Lipopeptides; Mannans; Survival Rate; Voriconazole | 2015 |